Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFLECTIONS B537-02: Ixifi vs Infliximab in RA
NCT02222493Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2014
- Primary completion
- Jun 2016
- Modality
- Monoclonal Antibodies
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of infliximab in rheumatoid arthritis (RA) (2 arms), sponsored by Pfizer. Primary endpoint: American College of Rheumatology 20% Response at 14 weeks. Started Aug 2014; status: completed.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02222493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02222493.